EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSTUG00000039629
Gene Symbol: GABRG3
3 Cross references
211 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSTUG00000026684
Gene Symbol: GABRG3
3 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSSTUG00000037785
Gene Symbol: GABBR1
3 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1-Like

Ensembl ID : ENSSTUG00000046011
Gene Symbol: LOC115177025
2 Cross references
192 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1-Like

Ensembl ID : ENSSTUG00000043361
Gene Symbol: LOC115175312
2 Cross references
183 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1-Like

Ensembl ID : ENSSTUG00000039938
Gene Symbol: LOC115181510
2 Cross references
179 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSSTUG00000042075
Gene Symbol: LOC115174040
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSSTUG00000047271
Gene Symbol: LOC115175547
3 Cross references
201 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSSTUG00000002066
Gene Symbol: LOC115203612
3 Cross references
182 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b-Like

Ensembl ID : ENSSTUG00000004478
Gene Symbol: LOC115166733
3 Cross references
182 Possible Orthologues:

Gamma-Secretase Subunit Pen-2-Like

Ensembl ID : ENSSTUG00000010045
Gene Symbol: LOC115164584
3 Cross references
177 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSSTUG00000012653
Gene Symbol: GCGR
3 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).